Harrow (HROW) Cash from Investing Activities Growth (5y) (2017 - 2026)
Harrow (HROW) Cash from Investing Activities Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.57% |
| Mar 31, 2026 | -140.98% |
| Dec 31, 2025 | -120.86% |
| Sep 30, 2025 | 4.35% |
| Jun 30, 2025 | 2.76% |
| Mar 31, 2025 | 4.93% |
| Dec 31, 2024 | -107.82% |
| Sep 30, 2024 | -49.85% |
| Jun 30, 2024 | 67.21% |
| Mar 31, 2024 | 19.43% |
| Dec 31, 2023 | 24.94% |
| Sep 30, 2023 | -98.88% |
| Jun 30, 2023 | -23.43% |
| Mar 31, 2023 | -246.03% |
| Dec 31, 2022 | 54.23% |
| Sep 30, 2022 | -40.25% |
| Jun 30, 2022 | 2.83% |
| Mar 31, 2022 | -13.68% |
| Sep 30, 2021 | -12.67% |
| Jun 30, 2021 | 28.10% |